Filing Overview
ORIC Pharmaceuticals, Inc. filed a Form 8-K on May 9, 2022, under Item 2.02 and Item 9.01(d). The filing announces the issuance of a press release reporting financial results for the fiscal quarter ended March 31, 2022.
Business Context and Reporting Period
ORIC Pharmaceuticals is a Delaware-incorporated biotechnology company with common stock listed on Nasdaq under the symbol ORIC. The reporting period covered is the quarter ended March 31, 2022.
Financial Results and Key Metrics
The filing itself does not provide the underlying revenue, net loss, cash flow, cash balance, operating expenses, margins, debt, liquidity, or other financial metrics. It incorporates by reference a press release designated as Exhibit 99.1, but the press release text is not included in the provided filing content.
Material Changes Versus Prior Period
The filing does not state specific changes versus the prior comparable period. Comparative results, if any, would need to be reviewed in Exhibit 99.1.
Guidance, Outlook, Risks, and Unusual Items
No guidance, financial outlook, management commentary, risk updates, contingencies, or unusual items are described in the provided Form 8-K text.
The financial-results disclosure was furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings, except where expressly stated.
Important Facts to Verify
- Obtain and review Exhibit 99.1, the May 9, 2022 financial-results press release.
- Verify quarterly revenue, research and development expense, general and administrative expense, operating loss, net loss, and loss per share.
- Verify cash, cash equivalents, investments, debt, quarterly cash burn, and estimated liquidity runway.
- Review any updated clinical-program milestones, corporate events, financing activity, guidance, or risk disclosures included in the press release.